Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7PY9O
|
|||
| Drug Name |
VH4524184
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Integrase (HIV IN) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05631704) A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ViiV Healthcare | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.